Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clemastine is a first-generation antihistamine used to relieve symptoms of allergies and the common cold such as sneezing, runny nose, watery eyes, itching, and hives. It acts primarily as a histamine H1 receptor antagonist by competitively blocking histamine at H1-receptor sites in the body[1][2][3][5]. This reduces allergic symptoms mediated by histamine release. Clemastine also exhibits anticholinergic properties and sedative side effects typical of first-generation antihistamines[5]. In addition to its established use for allergic conditions (allergic rhinitis/hay fever; urticaria), recent research has explored its potential for promoting remyelination in neurological diseases such as multiple sclerosis by enhancing oligodendrocyte differentiation and maturation[6][8]. Clemastine was patented in 1960 and is FDA-approved for allergy-related indications[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clemastine.